What is Iridex's gross profit margin?

What is the market's earnings forecast for Iridex next quarter?

What were the key takeaways from Iridex's earnings call?

What were the key takeaways from Iridex’s earnings call?

What does Iridex do and what are its main business segments?

Did Iridex beat or miss consensus estimates last quarter?

What factors drove the changes in Iridex's revenue and profit?

What is Iridex's latest dividend and current dividend yield?

- **Revenue Growth**: 8% FY2025 to $52.7M, Q4 up 16% YoY, guided 2026 at $51-53M (1-5% ex-Middle East).
- **Cost Efficiency**: 22% expense reduction, $165k/Q1 savings from G&A relocation, 2025 cash use down 71%.
- **Strategic Moves**: Transitioning manufacturing to cut costs, targeting 2027 gross margin improvement.
- **Key Risks**: Middle East conflict (5% revenue), macroeconomic challenges in Asia.

**【CEO Summary Section】**
- **Full Year 2025 Performance**: Revenue grew 8% to $52.7 million, with Q4 up 16% year-over-year. Operating expenses reduced by 22%, achieving first-time positive adjusted EBITDA and Q4 cash flow.
- **Cost Optimization Initiatives**: 
  - Relocating G&A to save $165k/Q1 and $600k/year by moving HQ.
  - Transitioning manufacturing to third-party contractors, targeting 2027 completion for gross margin improvement.
- **Product Highlights**: 
  - G6 probes sold 15,900 in Q4 (13,300 YoY), systems 44 (47 YoY). International growth despite Middle East conflict.
  - Retina segment: PASCAL adoption strong, Q4 revenue up 22% driven by system sales.
- **2026 Guidance**: Revenue $51-53 million (1-5% growth ex-Middle East), excluding $52.7M 2025 Middle East revenue.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: 
  - Revenue $14.7 million (16% YoY), gross margin 37% (down due to manufacturing costs).
  - Operating expenses $5.5 million (10% YoY decline), net loss $0.2 million.
  - Positive cash flow ($6 million) vs. $5.6 million prior, 2025 cash use down 71%.
- **2026 Outlook**: 
  - Operating expenses $19-19.5 million, focusing on reducing manufacturing costs.
  - Seasonality: Q1 22% of annual revenue, Q4 strongest.

**【Q&A Key Highlights】**
- **Middle East Impact**: 5% of revenue, excluded from 2026 guidance due to conflict.
- **Other Revenue Stability**: Minor fluctuations, no material trend.
- **G6 Pricing**: U.S. ASPs increased, systems sold with higher margins.
- **Retina Growth**: PASCAL adoption and global approvals expected to drive 1-5% growth.

IRIDEX Corporation(IRIX)-20260327-2025 Q4 Earnings call transcript

- **Revenue Growth**: 8% YoY to $12.5 million, supported by glaucoma and retina product sales.
- **Cost Efficiency**: 12% expense reduction to $5.4 million, with 25% nine-month savings.
- **Gross Margin Initiatives**: $165k quarterly savings from relocations; contract manufacturing to improve margins.
- **Regional Performance**: Europe and Latin America growing, Asia facing tariffs and currency challenges.
- **Financial Targets**: Q4 cash flow breakeven and 2025 positive EBITDA.

**【CEO Summary Section】**
- IRIDEX achieved 8% year-over-year revenue growth in Q3 2025, reaching $12.5 million, with operating expenses reduced by 12% to $5.4 million.
- The company is on track for positive cash flows in Q4 2025 and full-year adjusted EBITDA positivity, with a 25% reduction in operating expenses over nine months.
- Initiatives to enhance gross margins include negotiating with contract manufacturers and relocating functions to save $165,000 quarterly starting Q1 2026.
- Commercial success driven by glaucoma (30 G6 systems sold, 14,900 probes) and retina (10% growth in medical/surgical sales) products, despite Asia's challenges with tariffs and currency issues.

**【CFO Financial Commentary】**
- Q3 2025 gross margin was 32.1% (38.7% excluding a $0.8 million inventory write-down), with non-GAAP adjusted EBITDA improving by $1.3 million to a loss of $131,000.
- Cash decreased to $5.6 million, but the company expects Q4 cash flow breakeven and positive 2025 EBITDA.
- Revenue growth driven by glaucoma (13% increase) and retina (4% increase) products, offsetting surgical retina probe declines.

IRIDEX Corporation(IRIX)-20251112-2025 Q3 Earnings call transcript

- **Revenue Growth**: Q2 2025 revenue of $13.6M (+7% YoY, +14% QoQ) driven by Pascal and G6 systems.
- **Cost Efficiency**: 28% YoY operating expense reduction ($7.8M to $5.6M) through cost-cutting.
- **Profitability**: Net loss narrowed to $1.0M (-$0.06/share) from -$2.7M (-$0.16/share) YoY.
- **Cash Flow**: $6.8M cash, with $0.4M QoQ burn; on track for 2025 cash flow breakeven.
- **Key Risks**: Supply chain strain in Asia, regulatory delays in GmbH, pricing pressure in Latin America.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 revenue of $13.6M, up 7% YoY and 14% sequentially, driven by higher Pascal and G6 system sales.
- **Cost Efficiency**: Operating expenses reduced by 28% YoY ($7.8M to $5.6M) through cost-cutting programs initiated in Q4 2024.
- **Product Performance**: 
  - Retina segment: Pascal system sales exceeded expectations, with strong U.S. adoption and EMEA momentum.
  - Glaucoma segment: G6 probe sales over plan, despite supply constraints resolved by Q3.
- **Challenges**: 
  - Asia tariffs caused supply chain strain; Japan rollout delays.
  - Latin America pricing pressures offset by successful Pascal launch.
  - GmbH regulatory delays impacting international growth.
- **Future Plans**: 
  - Relocate to smaller, cheaper facility by Q3 2026 to reduce lease costs.
  - Shift to higher-margin disposable probes to improve gross margins.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: 
  - Retina: $8.0M (10% YoY growth)
  - Glaucoma: $3.3M (flat YoY)
  - Other: $2.2M (service revenue growth)
- **Gross Margin**: 34.5% (down from 40.7% YoY due to console sales mix, tariffs, and distributor margins).
- **Net Loss**: $1.0M (-$0.06/share) vs. -$2.7M (-$0.16/share) YoY, with cash burn reduced to $0.4M/Q.
- **Liquidity**: $6.8M cash (down $0.4M from Q1), with plans to achieve cash flow breakeven in 2025.
- **Key Metrics**: 
  - Adjusted EBITDA: $21,000 (vs. -$1.7M YoY)
  - Operating expense reduction: $2.2M YoY

IRIDEX Corporation (IRIX) Q2 2025 Earnings Call Transcript

- **Revenue stabilization**: $11.9M Q1 revenue with 8% growth in Cyclo G6 family, offsetting retina sales softness.
- **Profitability turnaround**: First two quarters of positive adjusted EBITDA, with 32% YoY OpEx reduction.
- **Strategic investment**: $10M from Novel to strengthen balance sheet and support U.S.-manufactured product advantage.
- **Gross margin expansion**: 42.5% (Q1 2025) vs. 37.9% (Q1 2024), driven by cost control and product mix.
- **Cash flow breakeven**: On track for 2025 with $7.2M cash and 31% YoY reduction in operating cash use.

**【CEO Business Overview】**
- IRIDEX achieved **$11.9M Q1 revenue**, marking the first two quarters of positive adjusted EBITDA in recent history.
- **Cost reduction initiatives**: Operating expenses decreased 32% YoY and 14% QoQ, with headcount-related costs down significantly.
- **Strategic partnership**: $10M investment from Novel Inspiration to strengthen balance sheet and support growth in laser-based medical systems.
- **Product momentum**: Cyclo G6 family revenue up 8% YoY, MP3 probe sales exceeded expectations, and EndoProbes outperformed forecasts.

**【CFO Financial Highlights】**
- **Gross margin improvement**: 42.5% (Q1 2025) vs. 37.9% (Q1 2024), driven by favorable product mix and lower manufacturing costs.
- **Adjusted EBITDA**: $0.4M vs. -$2.5M YoY, reflecting $2.9M improvement.
- **Cash position**: $7.2M post-Novel investment, with net cash used in operations down 31% YoY.
- **Tariff resilience**: Minimal direct exposure due to U.S.-based manufacturing, giving competitive pricing advantage.

**【Key Strategic Updates】**
- **Tariff impact**: U.S.-sourced supply chain mitigates risks; China exports remain immaterial.
- **Growth strategy**: Exploring partnerships, distribution agreements, or small acquisitions to expand product portfolio.
- **Cash flow breakeven**: On track for 2025 with disciplined expense management and stable revenue generation.
- **Market expansion**: Strong growth in EMEA glaucoma segment, India/Japan PASCAL system sales, and China retina recovery.


IRIDEX Corporation, Inc. (IRIX) Q1 2025 Earnings Call Transcript

- **Cost Efficiency Breakthrough**: Q4 2024 marks first positive adjusted EBITDA ($0.4M) with 24% YoY expense reduction, positioning for 2025 cash flow growth.
- **Glaucoma Market Shift**: LCD-driven 34% YoY system sales surge and 5% Probe volume increase highlight strategic product differentiation.
- **Strategic Capital Injection**: $10M at 50% premium to market, signaling investor confidence in IRIDEX's repositioning as a consolidated ophthalmology leader.
- **Q1 Momentum Signal**: Pre-announcement underscores management confidence in 2025 growth trajectory and shareholder value creation.

**【CEO Summary Section】**
- **Cost Reduction Success**: Completed Q4 cost-cutting program, achieving positive adjusted EBITDA ($0.4M) and cash flow for the first time in recent history. Operating expenses decreased 24% YoY to $6.1M.
- **Glaucoma Market Recovery**: Stabilization driven by November 2024 LCD limiting MIGS use, boosting Cyclo G6 Probe sales (+5% YoY to 13,300 units) and system sales (+34% YoY to 47 units).
- **Strategic Investment**: $10M from Novel Innovations at $2/share (premium to market), with $10M option for future growth. Investment aligns with IRIDEX's vision to enhance market leadership in retina and glaucoma.

**【CFO Financial Commentary】**
- **Revenue Growth**: Q4 2024 revenue $12.7M (+1.6% YoY, +10% QoQ), with Cyclo G6 product family up 9% YoY. Retina revenue down 3% YoY due to international capital delays.
- **Profitability Improvement**: Gross margin 44.0% vs 39.2% YoY. Net loss narrowed to $0.8M ($0.05/share) vs $3.0M ($0.18/share) YoY.
- **Liquidity**: $2.4M cash + $10M from Novel, supporting Q1 2025 positive cash flow outlook.

**【CEO Final Remarks】**
- **Q1 Pre-Announcement**: One-time event to open insider trading window and address undervaluation relative to Novel's $2/share investment. No change to future reporting practices.

Actual											-0.12	-0.2	-0.12	-0.01	-0.14	0.09	-0.14	-0.15	-0.15	-0.14	-0.11	-0.07	-0.13	-0.17	-0.11	-0.18	-0.21	-0.16	-0.12	-0.05	-0.1	-0.06	-0.09	-0.01
Forecast											-0.165	-0.225	-0.175	-0.105	-0.14	-0.155	-0.145	-0.11	-0.16	-0.155	-0.145	-0.11	-0.12	-0.11	-0.125	-0.05	-0.12	-0.12	-0.09	-0.05	-0.1	-0.09	-0.06	-0.02
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+27.27%	+11.11%	+31.43%	+90.48%	0.00%	+158.06%	+3.45%	-36.36%	+6.25%	+9.68%	+24.14%	+36.36%	-8.33%	-54.55%	+12.00%	-260.00%	-75.00%	-33.33%	-33.33%	0.00%	0.00%	+33.33%	-50.00%	+50.00%

Actual	--	--	--	--	--	--	--	--	--	--	9.02M	6.22M	8.80M	12.30M	11.96M	13.43M	13.26M	15.25M	13.39M	13.76M	14.63M	15.20M	13.71M	12.86M	12.85M	12.46M	11.76M	12.63M	11.58M	12.70M	11.90M	13.57M	12.48M	14.72M
Forecast	--	--	--	--	--	--	--	--	--	--	9.51M	5.04M	7.79M	12.26M	9.90M	11.61M	11.90M	14.69M	13.41M	13.92M	13.87M	15.16M	13.64M	14.23M	13.48M	14.90M	12.00M	12.80M	12.50M	12.80M	12.10M	13.10M	13.10M	14.74M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-5.13%	+23.36%	+13.05%	+0.39%	+20.77%	+15.65%	+11.42%	+3.85%	-0.21%	-1.22%	+5.54%	+0.20%	+0.48%	-9.67%	-4.70%	-16.39%	-1.99%	-1.32%	-7.35%	-0.81%	-1.69%	+3.60%	-4.70%	-0.11%

IRIX

IRIX fundamentals

IRIX Q4 2025 Earnings

Earnings Call

You can ask Aime

IRIX

IRIX fundamentals

IRIX Q4 2025 Earnings

Earnings Call

IRIX Earnings Call Summary for Q4/20255:00 PM on Mar 26, 2026

IRIX Earnings Call Summary for Q3/20255:00 PM on Nov 11, 2025

IRIX Earnings Call Summary for Q2/20255:00 PM on Aug 12, 2025

IRIX Earnings Call Summary for Q1/20255:00 PM on May 13, 2025

IRIX Earnings Call Summary for Q4/20245:00 PM on Mar 27, 2025

You can ask Aime